Impact of individual comorbidities on survival of patients with myelofibrosis

Mostra el registre complet Registre parcial de l'ítem

  • dc.contributor.author García-Fortes, María
  • dc.contributor.author Hernández-Boluda, Juan Carlos
  • dc.contributor.author Alvarez-Larrán, Alberto
  • dc.contributor.author Raya, José M.
  • dc.contributor.author Angona Figueras, Anna
  • dc.contributor.author Estrada, Natalia
  • dc.contributor.author Fox, Laura
  • dc.contributor.author Cuevas, Beatriz
  • dc.contributor.author García-Hernández, María C.
  • dc.contributor.author Gómez-Casares, Maria-Teresa
  • dc.contributor.author Ferrer-Marín, Francisca
  • dc.contributor.author Saavedra, Silvana
  • dc.contributor.author Cervantes, Francisco
  • dc.contributor.author García-Delgado, Regina
  • dc.contributor.author Grupo Español de Enfermedades Mieloproliferativas Filadelfia Negativas Gemfin
  • dc.date.accessioned 2023-01-24T08:07:45Z
  • dc.date.available 2023-01-24T08:07:45Z
  • dc.date.issued 2022
  • dc.description.abstract The comorbidity burden is an important risk factor for overall survival (OS) in several hematological malignancies. This observational prospective study was conducted to evaluate the impact of individual comorbidities on survival in a multicenter series of 668 patients with primary myelofibrosis (PMF) or MF secondary to polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). Hypertension (hazard ratio (HR) = 4.96, p < 0.001), smoking (HR = 5.08, p < 0.001), dyslipidemia (HR = 4.65, p < 0.001) and hepatitis C virus (HCV) (HR = 4.26, p = 0.015) were most adversely associated with OS. Diabetes (HR = 3.01, p < 0.001), pulmonary disease (HR = 3.13, p < 0.001) and renal dysfunction (HR = 1.82, p = 0.037) were also associated with an increased risk of death. Multivariate analysis showed that pulmonary disease (HR = 2.69, p = 0.001), smoking (HR = 3.34, p < 0.001), renal dysfunction (HR = 2.08, p = 0.043) and HCV (HR = 11.49, p = 0.001) had a negative impact on OS. When ruxolitinib exposure was included in the model, the effect of each comorbidity on survival was modified. Therefore, individual comorbidities should be taken into account in determining the survival prognosis for patients with MF.
  • dc.format.mimetype application/pdf
  • dc.identifier.citation García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, et al. Impact of individual comorbidities on survival of patients with myelofibrosis. Cancers (Basel). 2022 May 9;14(9): 2331. DOI: 10.3390/cancers14092331
  • dc.identifier.doi http://dx.doi.org/10.3390/cancers14092331
  • dc.identifier.issn 2072-6694
  • dc.identifier.uri http://hdl.handle.net/10230/55418
  • dc.language.iso eng
  • dc.publisher MDPI
  • dc.rights Copyright © 2022 by García-Fortes M, Hernández-Boluda JC, Álvarez-Larrán A, Raya JM, Angona A, Estrada N, et al. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
  • dc.rights.accessRights info:eu-repo/semantics/openAccess
  • dc.rights.uri http://creativecommons.org/licenses/by/4.0/
  • dc.subject.keyword Comorbidities
  • dc.subject.keyword Myelofibrosis
  • dc.subject.keyword Prognosis
  • dc.subject.keyword Survival
  • dc.title Impact of individual comorbidities on survival of patients with myelofibrosis
  • dc.type info:eu-repo/semantics/article
  • dc.type.version info:eu-repo/semantics/publishedVersion